Clinical Trial Update: Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate [Phase 2]

View source ↗

Summary

A Phase II trial evaluating a radiolabeled monoclonal antibody for progressive metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Radiolabeled monoclonal antibody

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED